Genetic disease biotech Stoke Therapeutics sets terms for $101 million IPO

Shutterstock photo

Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, announced terms for its IPO on Friday.

The Bedford, MA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Stoke Therapeutics would command a fully diluted market value of $509 million.

Stoke Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol STOK. J.P. Morgan, Cowen and Credit Suisse are the joint bookrunners on the deal. It is expected to price June 18, 2019.

The article Genetic disease biotech Stoke Therapeutics sets terms for $101 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?